Biogenentech

Quote

anonymous

Guest
WTF is going on at Genentech. Don't claim that you are all about doing good by your own people and don't claim that values are at the center of your hiring decisions. Just don't do it.
 


















anonymous said:
Yes, Biogen people brought in at key positions over Genentech internals for MS jobs. Just the beginning. These hires bring with them the baggage of deceit, self entitlement and overblown self worth.
Click to expand...

"bring in self entitlement and overblown self worth"? That is like bringing a cup of salt water to the ocean
 






Do the right thing Genentech HR! Hire within the very capable franchises you already have for MS! The Transplant franchise has tremendous talent, record of success and are ready to go!!!!
 












You clowns have no relationships in the MS market. The COEs don't want some newbie to MS calling on them. They want a seasoned pro who they have a long history with. This is fact sorry to tell you.
 












anonymous said:
PLEASE...A joke...You have MS experience; all these jobs are the same. Anyone can sell any therapeutic area. That is the fact! Get off your high horse - A-hole!
Click to expand...

You'll find out the hard way, douchebag.

The MS Neuros are unique to say the least. Everyone at Biogen, Novartis, Teva, & Genzyme hope you all have the attitude you do!
 












This MS person is a total idiot....How many people have sold in many unique disease states?
Get a grip! The product will sell itself numb nuts!

Don't hire just MS people; diversity is key to be successful; even a Biogen rep has expressed this!
 






anonymous said:
You'll find out the hard way, douchebag.

The MS Neuros are unique to say the least. Everyone at Biogen, Novartis, Teva, & Genzyme hope you all have the attitude you do!
Click to expand...

Here is where you messed up...Novartis is NOT respected in the MS market. And look to Novartis' misstep...they have a great product but can't climb passed a 9% national share because they hired no one with MS experience!
 






What is unique about MS is how some companies distort the data and resort to unscrupulous tactics to gain a perceived advantage in the market.

Genentech has a patient centric approach, a great patient support capability and a great product. We do not need Biogen scum to sell this product successfully. Amy B you ought to be ashamed... it all starts with you. The other franchises will not forget this.
 






anonymous said:
What is unique about MS is how some companies distort the data and resort to unscrupulous tactics to gain a perceived advantage in the market.

Genentech has a patient centric approach, a great patient support capability and a great product. We do not need Biogen scum to sell this product successfully. Amy B you ought to be ashamed... it all starts with you. The other franchises will not forget this.
Click to expand...

They are paying base pay at 185k it's all Biogen scum I am pissed.
 






All this chatter for nothing! OCRE will do well in PPMS where it has a clear advantage & label. Not long after it is launched it will see its first PML case and it will be over. The FDA will want a REMS/remediation plan and that is near impossible for a drug like this. B cell depletion/inhibition only makes sense as primary therapy in ONC where the patients are in life or death situations and you can't clearly link all the PML from B cell depletion to the drug itself, due to the number of other immunosuppresant drugs the patients are on. I give OCRE a year before the first PML shows up
 






anonymous said:
All this chatter for nothing! OCRE will do well in PPMS where it has a clear advantage & label. Not long after it is launched it will see its first PML case and it will be over. The FDA will want a REMS/remediation plan and that is near impossible for a drug like this. B cell depletion/inhibition only makes sense as primary therapy in ONC where the patients are in life or death situations and you can't clearly link all the PML from B cell depletion to the drug itself, due to the number of other immunosuppresant drugs the patients are on. I give OCRE a year before the first PML shows up
Click to expand...

Meaning that the Biogen transplants will be looking to leave for something else a year from now?
 






anonymous said:
What is unique about MS is how some companies distort the data and resort to unscrupulous tactics to gain a perceived advantage in the market.
Click to expand...

Can you provide some concrete examples of studies whose results were distorted? I see this claim being made a lot, but very little evidence to back it up. I can believe that in 2005 Biogen knew about the PML risk for several weeks before this information was released, but the information eventually was released, and the delay was clinically irrelevant for most patients (though it was relevant for investors). What else is there?
 






anonymous said:
B cell depletion/inhibition only makes sense as primary therapy in ONC where the patients are in life or death situations and you can't clearly link all the PML from B cell depletion to the drug itself, due to the number of other immunosuppresant drugs the patients are on.
Click to expand...

Ever heard of rituximab for RA? Anyway, who cares about a few PML cases? The annual risk of developing PML from rituximab among RA patients appears to be <1/10000. Let's be conservative, and say that the annual PML risk on ocrelizumab is 10 times higher than rituximab, giving an annual risk of 1/1000. (Which is still a lot lower than Tysabri for someone JC+.)

If you're a 40 year old male reading this board, you already have a 1/500 annual probability of death. Do you constantly freak out about the possibility of dying? If not, why should people with MS worry about PML from ocrelizumab? Sure, it may happen, but compared to the risks from MS itself, it just doesn't matter.
 






anonymous said:
They are paying base pay at 185k it's all Biogen scum I am pissed.
Click to expand...
That's not true, no one has received a base salary of 185k. Biogen reps are banging on the doors to get out and Mike J and cronies have paved the way. Who ever this Amy B is ... she messed up big when she turned over the keys to the castle.
 






No one is paying that kind of cash...if you have heard that consider that source. Go to Alexion I heard they were paying 170.....base.. when it came down to the real number it was 148-150 which is still too high.
 






Top Bottom
Back
Quote